Q1 Earnings Estimate for Nuvalent Issued By Leerink Partnrs

Nuvalent, Inc. (NASDAQ:NUVL - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Nuvalent in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will earn ($1.14) per share for the quarter. The consensus estimate for Nuvalent's current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Nuvalent's FY2025 earnings at ($4.60) EPS, FY2026 earnings at ($5.24) EPS and FY2027 earnings at ($4.11) EPS.

Several other research analysts have also weighed in on NUVL. UBS Group began coverage on shares of Nuvalent in a research note on Thursday, October 24th. They issued a "neutral" rating and a $100.00 price objective on the stock. BMO Capital Markets upped their price objective on shares of Nuvalent from $132.00 to $134.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. HC Wainwright restated a "buy" rating and set a $110.00 price target on shares of Nuvalent in a research note on Friday, January 17th. Finally, Wedbush reaffirmed an "outperform" rating and set a $115.00 price objective on shares of Nuvalent in a report on Monday, January 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $112.36.

Nuvalent Stock Down 0.4 %

Shares of NUVL stock traded down $0.29 during trading hours on Monday, reaching $80.95. 310,151 shares of the stock traded hands, compared to its average volume of 478,974. Nuvalent has a 1-year low of $61.79 and a 1-year high of $113.51. The business has a fifty day moving average price of $82.74 and a 200 day moving average price of $87.93. The firm has a market capitalization of $5.75 billion, a PE ratio of -23.33 and a beta of 1.38.

Nuvalent (NASDAQ:NUVL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.35). During the same quarter last year, the business posted ($0.59) EPS.

Hedge Funds Weigh In On Nuvalent

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. lifted its holdings in shares of Nuvalent by 4.8% during the 4th quarter. Ameritas Investment Partners Inc. now owns 3,676 shares of the company's stock worth $288,000 after acquiring an additional 167 shares during the period. Commonwealth Equity Services LLC increased its position in shares of Nuvalent by 13.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 2,618 shares of the company's stock worth $205,000 after purchasing an additional 309 shares in the last quarter. HighVista Strategies LLC increased its position in shares of Nuvalent by 1.1% during the 3rd quarter. HighVista Strategies LLC now owns 29,018 shares of the company's stock worth $2,969,000 after purchasing an additional 320 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in shares of Nuvalent during the 4th quarter worth about $27,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Nuvalent by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,147 shares of the company's stock worth $213,000 after purchasing an additional 382 shares in the last quarter. 97.26% of the stock is owned by institutional investors.

Insider Buying and Selling at Nuvalent

In other news, insider Henry E. Pelish sold 2,483 shares of the firm's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $79.68, for a total transaction of $197,845.44. Following the completion of the transaction, the insider now directly owns 59,981 shares of the company's stock, valued at approximately $4,779,286.08. This trade represents a 3.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alexandra Balcom sold 4,016 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $79.68, for a total transaction of $319,994.88. Following the transaction, the chief financial officer now directly owns 61,734 shares of the company's stock, valued at $4,918,965.12. The trade was a 6.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 83,800 shares of company stock valued at $6,812,164 in the last ninety days. Company insiders own 12.52% of the company's stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.